The Experts below are selected from a list of 210 Experts worldwide ranked by ideXlab platform
M. Grosshans - One of the best experts on this subject based on the ideXlab platform.
-
Photocontact dermatitis from ketoprofen and Tiaprofenic Acid: cross‐reactivity study in 12 consecutive patients
Contact Dermatitis, 1998Co-Authors: Anne Bottlaender, Jean‐nicolas Scrivener, Frederic Santinelli, Bernard Cribier, Ernest Heid Edouard, M. GrosshansAbstract:The arylpropionic Acid derivatives (APADs) ketoprofen and Tiaprofenic Acid can provoke photoallergic dermatitis. Possible cross-reactivity between APADs is of importance in patients using nonsteroidal anti-inflammatory drugs. Because of the similarities in chemical structures, we investigated patients with photoallergy to ketoprofen or Tiaprofenic Acid, in order to study cross-reactivity between APADs and a possible pattern of cross-reactivity between benzophenone-containing molecules, so as to determine the molecular basis of photoallergy to ketoprofen or Tiaprofenic Acid. 10 patients with photoallergy to topical ketoprofen, 2 with photoallergy to oral Tiaprofenic Acid, and 15 control subjects with no history of contact dermatitis from APADs, nor from benzophenone-containing molecules, were photopatch tested in triplicate with ketoprofen, Tiaprofenic Acid, other APADs (alminoprofen, fenoprofen, flurbiprofen, ibuprofen and naproxen), benzophenone-containing molecules (fenofibrate, oxybenzone, sulisobenzone), and unsubstituted benzophenone. 1 set was irradiated with UVA light, 1 with solar-simulated irradiation and 1 dark control. Tests were read at 2, 3 and 4 days. Patients reacted to both ketoprofen and Tiaprofenic Acid (12/12), fenofibrate (8/12), oxybenzone (3/12) and unsubstituted benzophenone (11/12), but not to other APADs, nor to sulisobenzone. Tests remained negative in control patients. Photoallergy is due to the benzophenone moiety of ketoprofen, or to the very similar thiophene-phenylketone of Tiaprofenic Acid, but not to their arylpropionic function. This induces cross-reactivity to fenofibrate and oxybenzone but not to APADs without a benzophenone moiety, which may therefore probably be used in such patients. Unsubstituted benzophenone should be added to standard phototesting series.
-
photocontact dermatitis from ketoprofen and Tiaprofenic Acid cross reactivity study in 12 consecutive patients
Contact Dermatitis, 1998Co-Authors: Anne Bottlaender, Jean‐nicolas Scrivener, Frederic Santinelli, Bernard Cribier, Ernest Heid Edouard, M. GrosshansAbstract:The arylpropionic Acid derivatives (APADs) ketoprofen and Tiaprofenic Acid can provoke photoallergic dermatitis. Possible cross-reactivity between APADs is of importance in patients using nonsteroidal anti-inflammatory drugs. Because of the similarities in chemical structures, we investigated patients with photoallergy to ketoprofen or Tiaprofenic Acid, in order to study cross-reactivity between APADs and a possible pattern of cross-reactivity between benzophenone-containing molecules, so as to determine the molecular basis of photoallergy to ketoprofen or Tiaprofenic Acid. 10 patients with photoallergy to topical ketoprofen, 2 with photoallergy to oral Tiaprofenic Acid, and 15 control subjects with no history of contact dermatitis from APADs, nor from benzophenone-containing molecules, were photopatch tested in triplicate with ketoprofen, Tiaprofenic Acid, other APADs (alminoprofen, fenoprofen, flurbiprofen, ibuprofen and naproxen), benzophenone-containing molecules (fenofibrate, oxybenzone, sulisobenzone), and unsubstituted benzophenone. 1 set was irradiated with UVA light, 1 with solar-simulated irradiation and 1 dark control. Tests were read at 2, 3 and 4 days. Patients reacted to both ketoprofen and Tiaprofenic Acid (12/12), fenofibrate (8/12), oxybenzone (3/12) and unsubstituted benzophenone (11/12), but not to other APADs, nor to sulisobenzone. Tests remained negative in control patients. Photoallergy is due to the benzophenone moiety of ketoprofen, or to the very similar thiophene-phenylketone of Tiaprofenic Acid, but not to their arylpropionic function. This induces cross-reactivity to fenofibrate and oxybenzone but not to APADs without a benzophenone moiety, which may therefore probably be used in such patients. Unsubstituted benzophenone should be added to standard phototesting series.
G J Fellows - One of the best experts on this subject based on the ideXlab platform.
-
bilateral ureteric obstruction secondary to the prolonged use of Tiaprofenic Acid
The British journal of clinical practice, 1997Co-Authors: J P Crew, R Donat, D Roskell, G J FellowsAbstract:: There is increasing awareness that the long-term use of the non-steroidal anti-inflammatory agent Tiaprofenic Acid (Surgam) is associated with a severe form of cystitis. The condition is usually reversible with complete resolution of symptoms on stopping the drug. We present a case of Tiaprofenic Acid-induced cystitis resulting in bilateral hydronephrosis suggesting ureteric obstruction. The previous reported cases are reviewed and the risks of delay in withdrawal of the drug and of permanent ureteric damage are discussed.
Anne Bottlaender - One of the best experts on this subject based on the ideXlab platform.
-
Photocontact dermatitis from ketoprofen and Tiaprofenic Acid: cross‐reactivity study in 12 consecutive patients
Contact Dermatitis, 1998Co-Authors: Anne Bottlaender, Jean‐nicolas Scrivener, Frederic Santinelli, Bernard Cribier, Ernest Heid Edouard, M. GrosshansAbstract:The arylpropionic Acid derivatives (APADs) ketoprofen and Tiaprofenic Acid can provoke photoallergic dermatitis. Possible cross-reactivity between APADs is of importance in patients using nonsteroidal anti-inflammatory drugs. Because of the similarities in chemical structures, we investigated patients with photoallergy to ketoprofen or Tiaprofenic Acid, in order to study cross-reactivity between APADs and a possible pattern of cross-reactivity between benzophenone-containing molecules, so as to determine the molecular basis of photoallergy to ketoprofen or Tiaprofenic Acid. 10 patients with photoallergy to topical ketoprofen, 2 with photoallergy to oral Tiaprofenic Acid, and 15 control subjects with no history of contact dermatitis from APADs, nor from benzophenone-containing molecules, were photopatch tested in triplicate with ketoprofen, Tiaprofenic Acid, other APADs (alminoprofen, fenoprofen, flurbiprofen, ibuprofen and naproxen), benzophenone-containing molecules (fenofibrate, oxybenzone, sulisobenzone), and unsubstituted benzophenone. 1 set was irradiated with UVA light, 1 with solar-simulated irradiation and 1 dark control. Tests were read at 2, 3 and 4 days. Patients reacted to both ketoprofen and Tiaprofenic Acid (12/12), fenofibrate (8/12), oxybenzone (3/12) and unsubstituted benzophenone (11/12), but not to other APADs, nor to sulisobenzone. Tests remained negative in control patients. Photoallergy is due to the benzophenone moiety of ketoprofen, or to the very similar thiophene-phenylketone of Tiaprofenic Acid, but not to their arylpropionic function. This induces cross-reactivity to fenofibrate and oxybenzone but not to APADs without a benzophenone moiety, which may therefore probably be used in such patients. Unsubstituted benzophenone should be added to standard phototesting series.
-
photocontact dermatitis from ketoprofen and Tiaprofenic Acid cross reactivity study in 12 consecutive patients
Contact Dermatitis, 1998Co-Authors: Anne Bottlaender, Jean‐nicolas Scrivener, Frederic Santinelli, Bernard Cribier, Ernest Heid Edouard, M. GrosshansAbstract:The arylpropionic Acid derivatives (APADs) ketoprofen and Tiaprofenic Acid can provoke photoallergic dermatitis. Possible cross-reactivity between APADs is of importance in patients using nonsteroidal anti-inflammatory drugs. Because of the similarities in chemical structures, we investigated patients with photoallergy to ketoprofen or Tiaprofenic Acid, in order to study cross-reactivity between APADs and a possible pattern of cross-reactivity between benzophenone-containing molecules, so as to determine the molecular basis of photoallergy to ketoprofen or Tiaprofenic Acid. 10 patients with photoallergy to topical ketoprofen, 2 with photoallergy to oral Tiaprofenic Acid, and 15 control subjects with no history of contact dermatitis from APADs, nor from benzophenone-containing molecules, were photopatch tested in triplicate with ketoprofen, Tiaprofenic Acid, other APADs (alminoprofen, fenoprofen, flurbiprofen, ibuprofen and naproxen), benzophenone-containing molecules (fenofibrate, oxybenzone, sulisobenzone), and unsubstituted benzophenone. 1 set was irradiated with UVA light, 1 with solar-simulated irradiation and 1 dark control. Tests were read at 2, 3 and 4 days. Patients reacted to both ketoprofen and Tiaprofenic Acid (12/12), fenofibrate (8/12), oxybenzone (3/12) and unsubstituted benzophenone (11/12), but not to other APADs, nor to sulisobenzone. Tests remained negative in control patients. Photoallergy is due to the benzophenone moiety of ketoprofen, or to the very similar thiophene-phenylketone of Tiaprofenic Acid, but not to their arylpropionic function. This induces cross-reactivity to fenofibrate and oxybenzone but not to APADs without a benzophenone moiety, which may therefore probably be used in such patients. Unsubstituted benzophenone should be added to standard phototesting series.
J P Crew - One of the best experts on this subject based on the ideXlab platform.
-
bilateral ureteric obstruction secondary to the prolonged use of Tiaprofenic Acid
The British journal of clinical practice, 1997Co-Authors: J P Crew, R Donat, D Roskell, G J FellowsAbstract:: There is increasing awareness that the long-term use of the non-steroidal anti-inflammatory agent Tiaprofenic Acid (Surgam) is associated with a severe form of cystitis. The condition is usually reversible with complete resolution of symptoms on stopping the drug. We present a case of Tiaprofenic Acid-induced cystitis resulting in bilateral hydronephrosis suggesting ureteric obstruction. The previous reported cases are reviewed and the risks of delay in withdrawal of the drug and of permanent ureteric damage are discussed.
Antona J Wagstaff - One of the best experts on this subject based on the ideXlab platform.
-
Tiaprofenic Acid a reappraisal of its pharmacological properties and use in the management of rheumatic diseases
Drugs, 1995Co-Authors: Greg L Plosker, Antona J WagstaffAbstract:: Tiaprofenic Acid is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of patients with rheumatic diseases and other clinical conditions of pain and inflammation. Like other propionic Acid derivatives, Tiaprofenic Acid is effective and generally well tolerated. Comparative studies in patients with rheumatoid arthritis or osteoarthritis receiving Tiaprofenic Acid 600 mg/day demonstrated improvements in pain intensity, duration of morning stiffness, articular index and other clinical variables which were similar to those achieved with alternative NSAIDs. Tolerability was also comparable between Tiaprofenic Acid and other NSAIDs in most trials; the most frequently reported adverse events involved the gastrointestinal tract. Some studies showed a trend towards fewer patient withdrawals because of adverse events with Tiaprofenic Acid than with NSAIDs such as indomethacin. Current evidence suggests that nonbacterial cystitis is more likely to be associated with Tiaprofenic Acid than with other NSAIDs. This reaction should, however, be considered in the perspective of its infrequent occurrence and its typical reversibility, and against the wider background of the established usage of Tiaprofenic Acid and its overall tolerability profile which is similar to that of other NSAIDs. Unlike indomethacin, Tiaprofenic Acid was not associated with increased cartilage degradation in a recently completed large clinical trial known as LINK, which evaluated the effects of long term administration in patients with osteoarthritis of the knee. Thus, Tiaprofenic Acid is an established option among the range of NSAIDs used in the treatment of patients with rheumatic diseases, with efficacy and tolerability profiles that are relatively well characterised. The availability of a sustained release dosage form of Tiaprofenic Acid, which has a similar efficacy and tolerability profile to the standard formulation, provides a convenient once daily dosage regimen.
